Cardiovasculorenal Phenotyping in Fabry Disease Through Noninvasive Testing (VDFP)
Status
Conditions
Treatments
Details and patient eligibility
About
A longitudinal pilot study will be conducted to determine if there are additional testing modalities that are effective in broadly phenotyping subclinical dysfunction in patients with Fabry disease. Individual patients will undergo serial testing over a two-year period to evaluate for changes in their cardiovasculaorenal function during this period. Novel modalities evaluated will include measures of arterial stiffness, ambulatory blood pressure monitoring, cardiopulmonary exercise testing (CPET), and novel serum and urine biomarkers. The benefit of these measures being evaluated is that they are noninvasive, can be performed rapidly, and have reduced costs compared to the current standard screening modalities. Results from these evaluations will be compared to cMRI and standard urine and serum biomarkers performed clinically per local standard of care. The results will also be compared to both published normative data and data from patients with diabetes mellitus, who have a similar microvascular disease process to patients with Fabry disease.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Fabry patients with classical disease
- English speaking, which is needed to assist with obtaining a maximal effort CPET
- No medical contraindications to cardiopulmonary exercise testing or cMRI
- Either treatment naïve or current taking ERT
Exclusion criteria
- Physical limitation that would preclude exercise
- Currently prescribed non-ERT treatments for Fabry disease
Trial design
4 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Adam Powell, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal